Alert: Aggressive Marketing of High-Concentration Kratom Products & 7-OH Confusion Heightens Merchant Risk

The article discusses musician Brian Setzer's experience with kratom dependency, attributing it to aggressive marketing of "tonic" products, often high-concentration liquid extracts. It differentiates dependency from addiction but warns that the risk is heightened with strong, concentrated alkaloid products, many of which contain multiple doses in seemingly single-dose packaging. The piece highlights confusion between traditional kratom and 7-hydroxymitragynine (7-OH) based products, which are often marketed similarly. The FDA recommended in 2025 that products with elevated 7-OH be classified as Schedule I, leading to conflation by media and lawmakers.

So What for Merchants?

• No new immediate legal status changes for traditional kratom, but aggressive marketing of high-concentration products and 7-OH (which the FDA recommended for Schedule I classification in 2025) increases regulatory scrutiny and potential for future restrictions.
• Aggressive marketing claims and consumer dependency issues (as highlighted by public figures) elevate the risk of chargebacks, consumer complaints, and heightened scrutiny from payment processors, potentially impacting merchant account stability.
• The widespread confusion between traditional kratom and high-concentration 7-OH products, often marketed similarly, increases the risk of regulatory intervention or shipping complications if authorities conflate these distinct substances.

Source: Kratom Science via Sentinel Newsroom